AAP
CYTK icon

Arax Advisory Partners’s Cytokinetics CYTK Stock Holding History

Arax Advisory Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.8K Buy
596
+564
+1,763% +$40.5K ﹤0.01% 3254
2026
Q1 		$2.11K Sell
32
-338
-91% -$21.5K ﹤0.01% 3094
2025
Q4 		$23.5K Buy
370
+208
+128% +$12.9K ﹤0.01% 2020
2025
Q3 		$8.9K Buy
+162
New +$6.67K ﹤0.01% 2647
2025
Q1 		– Sell
-111
Closed -$5.22K – 2761
2024
Q4 		$5.22K Sell
111
-19
-15% -$987 ﹤0.01% 1729
2024
Q3 		$6.86K Buy
130
+19
+17% +$1.06K ﹤0.01% 1570
2024
Q2 		$6.01K Buy
+111
New +$6.7K ﹤0.01% 1512

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's CYTK Position: Q2 2026 in Review

Arax Advisory Partners increased its Cytokinetics (CYTK) stake by 1,763% in Q2 2026, buying an estimated $40.5K and bringing the position to 596 shares worth $50.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3254.

Arax Advisory Partners first reported a position in CYTK in Q2 2024 and has held it in 7 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Arax Advisory Partners held 596 shares of Cytokinetics worth $50.8K as of Q2 2026.
  • Arax Advisory Partners bought 564 Cytokinetics shares in Q2 2026, an estimated $40.5K.
  • Cytokinetics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3254 holding.
  • Arax Advisory Partners first reported a position in Cytokinetics in Q2 2024 and has held it in 7 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.